MX2013013752A - Pirfenidona y tratamiento anti-fibrotico en pacientes seleccionados. - Google Patents
Pirfenidona y tratamiento anti-fibrotico en pacientes seleccionados.Info
- Publication number
- MX2013013752A MX2013013752A MX2013013752A MX2013013752A MX2013013752A MX 2013013752 A MX2013013752 A MX 2013013752A MX 2013013752 A MX2013013752 A MX 2013013752A MX 2013013752 A MX2013013752 A MX 2013013752A MX 2013013752 A MX2013013752 A MX 2013013752A
- Authority
- MX
- Mexico
- Prior art keywords
- pirfenidone
- selected patients
- fibrotic therapy
- fibrotic
- therapy
- Prior art date
Links
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003073 pirfenidone Drugs 0.000 title abstract 2
- 230000003510 anti-fibrotic effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489936P | 2011-05-25 | 2011-05-25 | |
| US201161490057P | 2011-05-26 | 2011-05-26 | |
| US201161523047P | 2011-08-12 | 2011-08-12 | |
| US201161524961P | 2011-08-18 | 2011-08-18 | |
| PCT/US2012/039538 WO2012162592A1 (en) | 2011-05-25 | 2012-05-25 | Pirfenidone and anti-fibrotic therapy in selected patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013013752A true MX2013013752A (es) | 2014-08-01 |
Family
ID=47217770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013752A MX2013013752A (es) | 2011-05-25 | 2012-05-25 | Pirfenidona y tratamiento anti-fibrotico en pacientes seleccionados. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150164874A1 (https=) |
| EP (1) | EP2713732A4 (https=) |
| JP (1) | JP6170040B2 (https=) |
| KR (1) | KR20140022048A (https=) |
| AU (1) | AU2012258575B2 (https=) |
| CA (1) | CA2835438A1 (https=) |
| HK (1) | HK1197159A1 (https=) |
| IL (1) | IL229226A0 (https=) |
| MX (1) | MX2013013752A (https=) |
| SG (1) | SG195110A1 (https=) |
| WO (1) | WO2012162592A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5587184B2 (ja) | 2007-06-20 | 2014-09-10 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 繊維症阻害剤としての置換ｎ−アリールピリジノン |
| JP2014507474A (ja) * | 2011-03-08 | 2014-03-27 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換ｎ−アリールピリジノン |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| JP6799201B2 (ja) * | 2013-07-31 | 2020-12-16 | アヴァリン ファーマ インク． | エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用 |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| EP3194446B1 (en) | 2014-09-18 | 2022-10-26 | Cedars-Sinai Medical Center | Compositions and methods for treating fibrosis |
| ES2764840T3 (es) * | 2015-01-28 | 2020-06-04 | Univ Bordeaux | Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica |
| WO2016140714A1 (en) * | 2015-03-05 | 2016-09-09 | The General Hospital Corporation | Novel compositions and uses of metformin agents |
| KR20190122806A (ko) * | 2017-03-13 | 2019-10-30 | 장피트 | 조합 치료요법용 약학 조성물 |
| KR20200044066A (ko) * | 2017-08-22 | 2020-04-28 | 바이오젠 엠에이 인코포레이티드 | 항-알파(v)베타(6) 항체를 함유하는 약제학적 조성물 및 투약 요법 |
| WO2020236615A1 (en) * | 2019-05-17 | 2020-11-26 | The Regents Of The University Of California | Mps modified peptides and use thereof |
| CN112239507A (zh) * | 2019-07-17 | 2021-01-19 | 鸿运华宁（杭州）生物医药有限公司 | ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用 |
| EP3821946A1 (en) * | 2019-11-12 | 2021-05-19 | Université de Strasbourg | Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases |
| KR20220109439A (ko) | 2019-12-04 | 2022-08-04 | 이도르시아 파마슈티컬스 리미티드 | 섬유증 질환의 치료에서 사용하기 위한 아제티딘 lpa1 수용체 길항제와 피르페니돈 및/또는 닌테다닙의 조합 |
| EP4117659A4 (en) * | 2020-03-13 | 2024-04-03 | Puretech Lyt 100, Inc. | Methods of treating respiratory disease with deupirfenidone |
| CN114617890A (zh) * | 2020-12-08 | 2022-06-14 | 四川夏派森医药科技有限公司 | DH404在治疗SARS-CoV-2感染中的应用 |
| CN112640887B (zh) * | 2020-12-25 | 2022-05-13 | 武汉睿健医药科技有限公司 | 一种神经干细胞冻存液及其应用 |
| WO2022266370A1 (en) * | 2021-06-17 | 2022-12-22 | Aria Pharmaceuticals, Inc. | Sparsentan for treating idiopathic pulmonary fibrosis |
| CN114097807B (zh) * | 2021-11-25 | 2023-05-05 | 兰州大学 | 巴多索隆类化合物在抗农业病原真菌中的用途 |
| WO2023192646A1 (en) * | 2022-03-31 | 2023-10-05 | Puretech Lyt 100, Inc. | Methods of treating fibrotic- and collagen-mediated diseases and disorders with deupirfenidone |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE420878T1 (de) * | 2000-02-18 | 2009-01-15 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
| AU2003244922A1 (en) * | 2002-06-28 | 2004-01-19 | The Administrators Of The Tulane Educational Fund | 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating pulmonary fibrosis |
| US20070092488A1 (en) * | 2003-05-16 | 2007-04-26 | Intermune Inc. | Methods of treating idiopathic pulmonary fibrosis |
| WO2005110478A2 (en) * | 2004-04-13 | 2005-11-24 | Intermune, Inc. | Combination therapy for treating fibrotic disorders |
| WO2007119214A2 (en) * | 2006-04-13 | 2007-10-25 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| CA2914170C (en) * | 2006-09-08 | 2018-10-30 | Abbvie Bahamas Ltd. | Interleukin-13 binding proteins |
| JP5587184B2 (ja) * | 2007-06-20 | 2014-09-10 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 繊維症阻害剤としての置換ｎ−アリールピリジノン |
| AU2010206543A1 (en) * | 2009-01-26 | 2011-07-07 | Intermune, Inc. | Methods for treating acute myocardial infarctions and associated disorders |
| GB2474748B (en) * | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
-
2012
- 2012-05-25 HK HK14109929.1A patent/HK1197159A1/xx unknown
- 2012-05-25 SG SG2013086541A patent/SG195110A1/en unknown
- 2012-05-25 WO PCT/US2012/039538 patent/WO2012162592A1/en not_active Ceased
- 2012-05-25 KR KR1020137028921A patent/KR20140022048A/ko not_active Ceased
- 2012-05-25 US US14/373,276 patent/US20150164874A1/en not_active Abandoned
- 2012-05-25 AU AU2012258575A patent/AU2012258575B2/en not_active Ceased
- 2012-05-25 MX MX2013013752A patent/MX2013013752A/es not_active Application Discontinuation
- 2012-05-25 EP EP12788732.1A patent/EP2713732A4/en not_active Withdrawn
- 2012-05-25 JP JP2014512134A patent/JP6170040B2/ja not_active Expired - Fee Related
- 2012-05-25 CA CA2835438A patent/CA2835438A1/en not_active Abandoned
-
2013
- 2013-11-04 IL IL229226A patent/IL229226A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014518880A (ja) | 2014-08-07 |
| NZ617415A (en) | 2017-07-28 |
| CA2835438A1 (en) | 2012-11-29 |
| KR20140022048A (ko) | 2014-02-21 |
| US20150164874A1 (en) | 2015-06-18 |
| EP2713732A1 (en) | 2014-04-09 |
| WO2012162592A1 (en) | 2012-11-29 |
| AU2012258575A1 (en) | 2013-11-21 |
| JP6170040B2 (ja) | 2017-07-26 |
| IL229226A0 (en) | 2014-01-30 |
| EP2713732A4 (en) | 2014-12-03 |
| SG195110A1 (en) | 2013-12-30 |
| AU2012258575B2 (en) | 2017-03-02 |
| HK1197159A1 (en) | 2015-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG195110A1 (en) | Pirfenidone and anti-fibrotic therapy in selected patients | |
| ZA201409334B (en) | N-substituted benzamides and their use in the treatment of pain | |
| IL231536A (en) | Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases | |
| NZ707477A (en) | Activin-actrii antagonists and uses for treating bone and other disorders | |
| MX356525B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
| SI2935303T1 (sl) | 4'-fluoro-nukleozidi, 4'-fluoro-nukleotidi in njihovi analogi za zdravljenje HCV | |
| NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| IL221874A (en) | History of pyrimidine and their use in the treatment of respiratory diseases such as copd | |
| MX364220B (es) | Metodos de tratamientos de fibrosis. | |
| PH12015502302A1 (en) | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | |
| ZA201402452B (en) | Novel pyrimethanil formulations and uses thereof in the treatment of crops | |
| MX2015013755A (es) | Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis. | |
| GB2515440B (en) | Vesicular Formulations for use in the treatment of Rosacea | |
| ZA201307058B (en) | Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment | |
| GB2510524A (en) | Pulmonary hypertension | |
| ZA201503266B (en) | Pyidone derivatives and uses thereof in the treatment of tuberculosis | |
| IL230751A0 (en) | New peptides, preparations containing them and used in methods to treat metabolic, cardiac and immune diseases | |
| MX362111B (es) | Un metodo para mejorar la funcion hepatica. | |
| MX2013012551A (es) | Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares. | |
| PT2699545T (pt) | Novos derivados amino-pirrolínicos, sua utilização na prevenção e/ou tratamento do síndrome metabólico | |
| EP2934699A4 (en) | PLOD2 GENE STIMULATORS AND USE OF SAID STIMULATORS FOR TREATING SKIN | |
| TN2013000404A1 (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease | |
| TN2015000236A1 (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis | |
| UA70775U (ru) | Способ лечения менингококцемии у детей | |
| ZA201403477B (en) | Apricitabine and pi combination therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD | Licence granted | ||
| FA | Abandonment or withdrawal |